Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve
Recruiting
Observational Study
Transcatheter Aortic Valve Replacement (TAVR)
Aortic-Stenosis
Aortic Insufficiency
Degenerative Valve Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Institut für Pharmakologie und Präventive Medizin · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Evaluation of clinical outcomes and valve performance of the SAPIEN 3 Ultra Resilia (S3UR) valve over 10 years.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* Adult patients (≥18 years)
* Patients with severe aortic stenosis undergoing transfemoral TAVI on their native valve with S3UR valve
* Patient is willing to attend the follow-up visits up to 10 years at the center
Exclusion criteria:
* Lack of written informed consent
* Emer…
Contacts